Document is current
Any future updates will be listed below
-
Authors
Haack, Beatrice https://orcid.org/0009-0003-9615-824X
Engel, Johanna
Pauwels, Philipp
Toto, Sermin
Bleich, Stefan
Seifert, Johanna
Grohmann, Renate
Heinze, Martin
Zolk, Oliver
Proskynitopoulos, Phileas
Greiner, Timo
Schneider, Michael
-
Funding
Funding for this research was provided by:
Medizinische Hochschule Brandenburg CAMPUS GmbH
- License Information
-
More Information
Article History
Received: 27 May 2025
Accepted: 7 August 2025
First Online: 4 September 2025
Declarations
:
: Financial interests: ST is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker honoraria from Janssen-Cilag, Lundbeck/Otsuka, Recordati Pharma GmbH, ROVI GmbH and Servier. JS took part in two educational events sponsored by Otsuka/Lundbeck. The research presented in this manuscript did not receive any specific grants or funding. The AMSP drug safety project is facilitated by nonprofit associations in Germany, Austria, and Switzerland. The AMSP project has been supported with unrestricted educational and research grants since 1993 by the following companies: German companies: Abbott GmbH & Co. KG, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE–O/R/N, Bayer Vital GmbH, Boehringer Mannheim GmbH, Bristol-Myers-Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, Esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Novartis Pharma GmbH, Nordmark Arzneimittel GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Recordati Pharma GmbH, Rhone-Poulenc Rohrer, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr. Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH and Wyeth-Pharma GmbH. Austrian companies: Astra Zeneca Österreich GmbH, Boehringer Ingelheim Austria, Bristol-Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform and Wyeth Lederle Pharma GmbH. Swiss companies: AHP (Schweiz) AG, AstraZeneca AG, Bristol-Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Organon AG, Pfizer AG, Pharmacia, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthelabo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Wyeth AHP (Suisse) AG and Wyeth Pharmaceuticals AG. BH, TG, MH, OZ, JE, RG, SB, PP, PP and MS declare no financial interest. Non-financial interests: BH, TG, MH, OZ, JE, PP, PP and MS declare no non-financial interest. SB, RG, and ST are project managers of the AMSP program.
: The evaluated data were obtained from a completely anonymized database, ensuring that subjects could not be traced. Evaluations based on AMSP data were approved by the Ethics Committee of the University of Munich and the Ethics Committee of the Hannover Medical School (Nr. 8100_BO_S_2018).
